RAMM PharmaXCNQ:RAMM 3-Year RORE % is 0.74 as of Jan. 2026. The stock has 4 warning signs investors should review. Among 939 Drug Manufacturers companies, RAMM Pharma ranks worse than 52.29% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
RAMM Pharma's 3-Year RORE % for the quarter that ended in Jan. 2026 was 0.74%.
The industry rank for RAMM Pharma's 3-Year RORE % or its related term are showing as below:
XCNQ:RAMM's 3-Year RORE % is ranked worse than 52.29% of 939
companies
in the Drug Manufacturers industry
Industry Median: 3.06
vs XCNQ:RAMM: 0.74
RAMM Pharma (XCNQ:RAMM) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
RAMM Pharma 3-Year RORE % Related Terms
RAMM Pharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2026 and 3-year before.
RAMM Pharma (XCNQ:RAMM) has a 3-Year RORE % of 0.74 as of Jan. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RAMM Pharma and its competitors. According to the industry distribution chart, RAMM Pharma ranks #491 out of 939 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is RAMM Pharma's 3-Year RORE % too high?
RAMM Pharma's current 3-Year RORE % is 0.74. The Drug Manufacturers industry median 3-Year RORE % is 3.06. RAMM Pharma's value of 0.74 is 75.8% below this industry median. Based on the distribution chart, RAMM Pharma ranks #491 out of 939 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does RAMM Pharma's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #491 out of 939 companies for 3-Year RORE %. This places RAMM Pharma in the lower half of its industry. The industry median 3-Year RORE % is 3.06. RAMM Pharma's value of 0.74 is 75.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current 3-Year RORE % of 0.74 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current 3-Year RORE % is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current 3-Year RORE % is 0.74 and 75.8% below the Drug Manufacturers industry median of 3.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current 3-Year RORE % is 0.74 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 